Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 12087097 
Mabuchi S, et al. (2002) Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 277, 33490-500 12087097
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S112-p - BAD (mouse)
Orthologous residues
BAD (human): S75‑p, BAD (mouse): S112‑p, BAD (rat): S113‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  ovarian cancer
 Relevant cell lines - cell types - tissues:  SW626 (ovarian)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
taxol increase
PD98059 taxol inhibit treatment-induced increase
wortmannin taxol no effect upon treatment-induced increase

S136-p - BAD (mouse)
Orthologous residues
BAD (human): S99‑p, BAD (mouse): S136‑p, BAD (rat): S137‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  ovarian cancer
 Relevant cell lines - cell types - tissues:  SW626 (ovarian)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt1 (mouse) transfection of inactive enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
taxol increase
wortmannin taxol inhibit treatment-induced increase

S259-p - RAF1 (mouse)
Orthologous residues
RAF1 (human): S259‑p, RAF1 (mouse): S259‑p, RAF1 (rat): S259‑p, RAF1 (chicken): S259‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  ovarian cancer
 Relevant cell lines - cell types - tissues:  SW626 (ovarian)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt1 (mouse) transfection of constitutively active enzyme, pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
taxol increase
LY294002 taxol inhibit treatment-induced increase
wortmannin taxol inhibit treatment-induced increase
PD98059 taxol no effect upon treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.